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Abstract
Heparanase is an endoglycosidase that specifically cleaves heparan sulfate side chains of heparan sulfate proteoglycans.
Utilizing an ELISA method capable of detection and quantification of heparanase, we examined heparanase levels in the
plasma and urine of a cohort of 29 patients diagnosed with type 2 diabetes mellitus (T2DM), 14 T2DM patients who
underwent kidney transplantation, and 47 healthy volunteers. We provide evidence that heparanase levels in the urine of
T2DM patients are markedly elevated compared to healthy controls (11626181 vs. 156629.6 pg/ml for T2DM and healthy
controls, respectively), increase that is statistically highly significant (P,0.0001). Notably, heparanase levels were appreciably
decreased in the urine of T2DM patients who underwent kidney transplantation, albeit remained still higher than healthy
individuals (P,0.0001). Increased heparanase levels were also found in the plasma of T2DM patients. Importantly, urine
heparanase was associated with elevated blood glucose levels, implying that glucose mediates heparanase upregulation
and secretion into the urine and blood. Utilizing an in vitro system, we show that insulin stimulates heparanase secretion by
kidney 293 cells, and even higher secretion is observed when insulin is added to cells maintained under high glucose
conditions. These results provide evidence for a significant involvement of heparanase in diabetic complications.
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Introduction
Heparanase is an endoglycosidase which cleaves heparan sulfate
(HS) side chains at a limited number of sites, activity that is
strongly implicated in cell dissemination associated with tumor
metastasis, inflammation and angiogenesis [1–4]. Utilizing an
ELISA method capable of detection and quantification of
heparanase [5], we have recently reported that heparanase levels
are elevated in the plasma of pediatric cancer patients, correlating
with their response to anticancer treatment [6]. Similarly, elevated
levels of heparanase were measured in the urine of bladder cancer
patients, associating with disease progression [7].
Emerging evidence indicate that heparanase is also engaged in
diabetes and related complications, primarily kidney dysfunction
[8,9]. Loss of HS was observed in several experimental and
human glomerulopathies, including diabetic nephropathy, min-
imal change disease, and membranous glomerulopathy [8],
where a decrease in HS inversely correlates with proteinuria
[10–13]. Decreased content of HS noted in the glomerular
capillary barrier is attributed, in part, to over-expression of
heparanase and, consequently, alteration of the glomerular
basement membrane and its filtration characteristics [14–22].
Applying our ELISA method, we have previously demonstrated
elevated levels of heparanase in the urine of a small group of
diabetic patients, elevation that was confirmed by increased
heparanase enzymatic activity in the urine of these patients
[5,23]. Here, we examined heparanase levels in the plasma and
urine of patients with type 2 diabetes mellitus (T2DM), T2DM
patients who underwent kidney transplantation and control
healthy volunteers. Heparanase levels were then correlated with
clinical and pathological data. We provide evidence that
heparanase levels are elevated in the urine and plasma of
T2DM patients and are reduced following kidney transplanta-
tion. Notably, glucose levels in the blood correlated with
increased heparanase levels in the urine (P=0.0001) and plasma
(p=0.003). Utilizing an in vitro system, we show that insulin
stimulates heparanase secretion by kidney 293 cells, and even
higher secretion is observed when insulin was added to cells
maintained under high glucose conditions. The results imply that
heparanase is engaged in diabetes and related complications and,




The study included 47 healthy volunteers (controls) and 43
T2DM patients, 14 of which underwent kidney transplantation at
the Rambam Health Care Campus (Haifa, Israel). The study was
approved by the institutional review board. Clinical records
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plasma levels of glucose, creatinine, HbA1C, and cholesterol),
treatment modalities and transplantation procedure. T2DM
patients were selected at the outpatient nephrology clinic and
characterized by albuminuria and near normal eGFR (i.e., 60–
70 ml/min) typical of stage I-II diabetic kidney disease. Patients
with early stage chronic kidney disease (i.e., close to normal
creatinine levels) were selected as these patients are the ones likely
to benefit from heparanase-based treatment modalities. Patients
with stage V kidney disease who were subjected to kidney
transplantation as replacement therapy due to diabetic nephrop-
athy were selected for the study.
Sample collection
A total of 3 ml peripheral blood was collected in EDTA-
containing tubes, centrifuged (1500 g, 15 min at 4uC), and the
supernatant was collected, aliquoted and kept at -80uC until use.
Urine was collected, centrifuged at 1500 g for 10 min to remove
cells and cell debris, and the supernatant was kept at 280
oC until
analyzed. All samples were thawed once.
ELISA
Quantification of heparanase by ELISA method was carried
essentially as described [5]. Briefly, wells of microtiter plates were
coated (18 h, 4uC) with 1 mg/ml of 1E1 anti-heparanase
monoclonal antibody (mAb) in 50 ml of coating buffer (0.05 M
Na2CO3, 0.05 M NaHCO3, pH 9.6). After blocking (1% BSA in
PBS, 1 h at 37uC), plasma (100 ml, diluted 1:1 with 0.5% BSA) or
urine (200 ml) samples were loaded in duplicates and incubated at
room temperature for 2 h, followed by the addition of anti-
heparanase polyclonal antibody 1453 (1 mg/ml) for additional 2 h.
HRP-conjugated goat anti-rabbit IgG (1:20,000; Jackson Immu-
noResearch, West Grove, PA) in blocking buffer was added (1 h)
and the reaction was visualized by the addition of 100 ml
chromogenic substrate (TMB) for 30 min. The reaction was
stopped with 100 mlH 2SO4 and absorbance at 450 nm was
measured with reduction at 630 nm using ELISA plate reader.
Plates were washed five times with washing buffer (PBS, pH 7.4,
containing 0.1% Tween 20) after each step. As a reference for
quantification, a standard curve was established by a serial dilution
of recombinant 8+50 (GS3) active heparanase enzyme (390 pg/
ml–25 ng/ml) [5–7]. The 1E1 mAb preferentially recognizes the
8+50 kDa active enzyme vs. the 65 kDa proenzyme [5].
Cell culture, heparanase secretion and immunoblotting
Heparanase-transfected human embryonic kidney 293 cells
stably expressing heparanase and control cells transfected with an
empty vector (Vo) have been described previously [24]. Hepar-
anase cDNA cloned in pcDNA3 vector was used to direct high
levels of expression in mammalian cells, driven by a strong viral
(CMV) promoter. While this vector is not appropriate for the study
of gene transcription, it is most suitable for post-transcriptional
and secretion studies. Cells were grown to confluence followed by
incubation for 20 h in serum-free medium. The medium was then
replaced by fresh serum-free medium and the cells were incubated
without or with the indicated concentration of insulin (represent-
ing the range of insulin oscillation [25]) for additional 2 h. In other
experiments, cells were grown in normal growth medium [i.e.,
0.45% (25 mM) glucose] or high glucose conditions [3%
(167 mM) glucose] without or with insulin. Conditioned medium
was collected and applied onto
35S-labeld ECM-coated dishes to
evaluate heparanase enzymatic activity (see below) or, following
enrichment on heparin-Sepharose beads, were subjected to
immunoblotting, as described [24].
Heparanase activity
Preparation of sulfate labeled ECM-coated dishes and determi-
nation of heparanase activity were performed as described in detail
elsewhere [24,26]. Briefly, medium conditioned by 293 cells
(5610
5–2610
6) was adjusted to pH 6.0, applied into 35 mm dishes
coated with
35S-labeled ECM and incubated for 8 h at 37uC. The
incubation medium containing sulfate-labeled degradation frag-
ments was subjected to gel filtration on a Sepharose CL-6B
column. Fractions (0.2 ml) were eluted with PBS and their
radioactivity counted in a b-scintillation counter. Degradation
fragments of HS side chains were eluted at 0.5, Kav,0.8 (peak
II, fractions 10–30). Nearly intact HSPG was eluted just after the
Vo (Kav,0.2, peak I, fractions 3–8) [24,26].
Statistical analysis
Values are expressed as means6SE or as medians with ranges.
Comparison of heparanase levels between the different groups was
evaluated using the non-parametric Mann–Whitney U test. The
non-parametric Spearman’s rank test was used to calculate
correlation between the different variables. A value of P,0.05
was considered significant. GraphPad Prism 4.0 (GraphPad
Software Inc., San Diego, CA, USA) was used for data analysis.
Ethics
The study was approved by the Institution (Rambam Health
Care Campus) Review Board. A written informed consent was
obtained from each participant.
Results
Heparanase levels are elevated in the urine and plasma
of T2DM patients
Heparanase levels were quantified in 29 type 2 diabetic patients
(T2DM), 14 T2DM patients who underwent kidney transplanta-
tion, and 47 healthy volunteers utilizing an ELISA method specific
for human heparanase [5]. Demographic data is summarized in
Table 1. The control group (30 male, 17 female, age 46610)
included individuals with normal blood glucose levels
(78.961.1 mg/dl; 4.4 mM), blood pressure (120/80 mmHg),
and kidney function (i.e., creatinine levels #1 mg/dl). In T2DM
patients (14 female, 15 male; age 56.2612; average length of
disease=14.3 years), plasma creatinine level was 1.2560.6 mg/dl,
blood glucose was 148.5618.3 mg/dl (8.3 mM) and HbA1c was
5.5–7.5%. Nine patients were treated with insulin while all the rest
were treated with oral anti-glycemic drugs such as Metformin and
Sulfanilurea (Glibetic). In transplanted patients (3 female, 11 male;
age 58.4612.6), plasma creatinine was 1.3860.75 mg/dl, glucose
was 135.6638.2 mg/dl (7.5 mM) and HbA1C was over 7%. We
selected patients that were transplanted 5.2 years in average prior
to blood and urine sampling, bearing functioning kidney and
exhibiting creatinine levels close to normal (Table 1).
Heparanase levels in the urine of T2DM patients were
markedly elevated compared to healthy controls (11626181 vs.
156629.6 pg/ml for T2DM and healthy controls, respectively;
Table 2, Fig. 1A), increase that is statistically highly significance
(P,0.0001). Heparanase levels were appreciably decreased in the
urine of T2DM patients who underwent kidney transplantation
(11626181 vs. 424676 pg/ml for T2DM and transplanted
patients, respectively; Table 2, Fig. 1A; p=0.04), albeit still higher
than healthy individuals (P,0.0001). A more representative view
of heparanase levels in the urine of T2DM and transplanted
patients is obtained by plotting median, rather than average values
(Fig. 1B). While a median value of 80 pg/ml was calculated for
healthy individuals (control), median values of 867 and 410 pg/ml
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(Fig. 1B). These results suggest that urinary heparanase originates
primarily from diabetes-related nephropathy.
Increased heparanase levels were also found in the plasma of
T2DM patients (352670.4 vs. 117616 pg/ml for T2DM and
control, respectively; P=0.001) (Table 2, Fig. 1C), as also reflected
by plotting median values (Fig. 1D). Heparanase levels in the
plasma of T2DM patients were decreased after kidney transplan-
tation (352670 pg/ml vs. 196646), though only approaching
statistical significance (P=0.07; Fig. 1C), likely due to the low
number of patients in this group. Thus, in T2DM, elevated
amounts of heparanase are found in the circulation, spread
systemically and may affect distant organs, tissues, and cells.
We have previously reported that heparanase enzymatic activity
is preferentially elevated in urine collected from type 1 diabetic
females vs. males [23]. We therefore analyzed heparanase levels
according to gender (Fig. 2A, B). No differences in heparanase
levels were observed in the urine of T2DM females and males
(Fig. 2A; Table 2). Interestingly, higher levels of heparanase were
quantified in the plasma of T2DM females compared to males
(4486110 and 225640 for females and males, respectively;
Fig. 2B, Table 2). This difference only approached statistical
significance (p=0.1). Accordingly, higher levels of plasma
heparanase were found in female patients who underwent kidney
transplantation compared with males (37269 and 148645,
respectively; Fig. 2B, Table 2), differences that are statistically
significance (p=0.04). Elevated heparanase levels in the plasma of
females vs. males may be due to estrogen shown to stimulate
heparanase expression by estrogen receptor-positive cells [27,28].
We next examined the association between heparanase levels in
the plasma and urine of patients and their blood glucose levels.
Notably, blood glucose was significantly associated with urine
(r=0.52, P=0.0001; Fig. 2C), and plasma heparanase (r=0.38,
P=0.003; Fig. 2D).
Insulin cooperates with glucose in stimulating
heparanase secretion
While the 65 kDa pro-heparanase includes a signal peptide
(Met
1-Ala
35) and is readily secreted, secretion of active (8+50 kDa)
heparanase is tightly regulated [2,24]. The association between
blood glucose and urine heparanase levels led us to hypothesize
that glucose, insulin or combination of the two, stimulate
heparanase secretion. In order to examine this possibility,
heparanase-transfected human embryonic kidneys (HEK)-293
cells were left untreated or stimulated with increasing concentra-
tions of insulin. Conditioned medium was collected after 2 h and
subjected to immunoblotting applying anti-heparanase antibody.
No significant change in the levels of latent 65 kDa heparanase
was observed (Fig. 3A). In contrast, insulin stimulated secretion of
the active 50 kDa heparanase (Fig. 3A). Interestingly, low
concentrations of insulin appeared more effective than high doses
(10, 50 vs. $100 pM; Fig. 3A). Densitometry analysis revealed a
nearly 4-fold increase in heparanase (50 kDa) secretion in response
to low vs. high insulin concentrations (Fig. 3A, third panel).
Accordingly, heparanase activity was markedly increased in the
conditioned medium of cells stimulated with insulin at low
concentrations (not shown). Even higher stimulation of heparanase
secretion was observed in cells grown under high glucose levels
(3%; 167 mM) and treated with low concentrations (10–100 pM)
of insulin (Fig. 3A). Thus, while insulin stimulated heparanase
Table 1. Demographic description of enrolled individuals.
Urine heparanase (pg/ml) Control (n) T2DM (n) Transplanted (n)
Male 169641 (26) 12796270 (15) 394695 (11)
Female 141642 (21) 10376244 (14) 5166100 (3)
Average 6 SE 156629 11626181 424676
Total 47 29 14
Plasma heparanase (pg/ml) Control (n) T2DM (n) Transplanted (n)
Male 110624 (18) 225640 (6) 148645 (11)
Female 125621 (18) 4486110 (8) 372697 (3)
Average 6 SE 117616 352670 196646
Total 36 14 14
doi:10.1371/journal.pone.0017312.t001
Table 2. Heparanase levels in the urine and plasma of healthy volunteers (control), type 2 diabetic patients (T2DM) and T2DM
patients who underwent kidney transplantation.
Healthy control T2DM T2DM+ transplantation
N4 7 2 9 1 4
% Male 64 52 78
Age (years) 46.1610 56.2612 58.4612.6
Blood creatinine (mg/dl) 160.1 1.2560.6 1.3860.75
eGFR (MDRD, ml/min) 75.762.7 62.0364.7 68.6468.6
Glucose, mg/dl (mM) 78.961.1 (4.4) 148.5618.3 (8.3) 135.6638.2 (7.5)
doi:10.1371/journal.pone.0017312.t002
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(0.45%; 25 mM) (Fig. 3A, third panel), nearly 8-fold increase in
heparanase secretion was observed in cells grown in 3% (167 mM)
glucose and incubated with insulin (Fig. 3A). Accordingly, a higher
heparanase activity was measured in medium conditioned by cells
stimulated with insulin under high glucose (Fig. 3B). Co-operation
between glucose and insulin in stimulating both latent (65 kDa)
and active (50 kDa) heparanase secretion was similarly demon-
strated by kinetics studies (Fig. 3C). Evidently, the combination of
insulin and glucose did not accelerate heparanase secretion but
rather increased its magnitude (Fig. 3C). The secreted active
50 kDa heparanase most likely originates from lysosomes. This is
concluded from a parallel enhanced secretion of the active
(27 kDa) form of cathepsin D, a lysosome-resident protease
(Fig. 3A, second panel), and the re-distribution of heparanase-
containing vesicles in cells treated with insulin (Fig. 4). Thus, while
in un-stimulated cells heparanase was mainly detected in endocytic
vesicles residing perinuclearly (Fig. 4, Con), heparanase-positive
vesicles appeared redistributed towards the cell periphery
following insulin treatment (Fig. 4, Ins). This pattern of vesicles
relocation is in agreement with previous characterization of
mechanisms that facilitate secretion of active heparanase [24].
Discussion
While heparanase function in tumor biology is well documented
[2,4,29] and heparanase inhibitory compounds are being
developed as anti-cancer drugs [4,30–35], emerging evidence
indicate that heparanase is also engaged in several other
pathological disorders. Of increasing importance is the apparent
role of heparanase in diabetes and related complications, primarily
diabetic nephropathy [8,9]. Expression of heparanase is up-
Figure 1. Determination of heparanase levels in urine (A, B) and plasma (C, D) of individuals from the study groups. Shown are
average (6SE; A, C) and median (B, D) values quantified by an ELISA method, as described under ‘Materials and Methods’.
doi:10.1371/journal.pone.0017312.g001
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diseases [16,17], possibly destructing the permselective properties
of HS. Heparanase activity correlates with damage and dysfunc-
tion of the glomerular basement membrane, leading in many cases
to proteinuria [9,22,23]. Results presented in this study add
another layer of evidence for the causal involvement of heparanase
in diabetes. Clearly, heparanase levels are significantly elevated in
the urine of type 2 diabetic patients (Fig. 1A, B). This is in
agreement with previous publications demonstrating increased
heparanase activity [23] and protein levels [18] in the urine of a
small group of diabetes patients. Decreased urine heparanase
levels in diabetic patients who underwent kidney transplantation
suggest that urinary heparanase originates primarily from
diabetes-associated kidney failure. Indeed, immunohistochemical
analysis showed that heparanase is expressed in tubular epithelial
cells but not in glomeruli of normal kidney, while its expression is
upregulated in the glomeruli and tubular epithelial cells in kidneys
with diabetic nephropathy [17,18]. It should be kept in mind that
transplanted patients are treated with immunosuppressive drugs,
in addition to diabetes-related medication, which may affect
heparanase secretion.
The observed association with blood glucose levels (Fig. 2C)
may imply that glucose is involved in heparanase regulation.
Previously, glucose has been shown to stimulate heparanase gene
expression in rat glomerular epithelial cells and human embryonic
kidney 293 cells, associating with decreased levels of surface HS
[18]. Our results suggest that, in addition, glucose stimulates
heparanase secretion. This is best demonstrated by enhanced
heparanase secretion from cultured kidney-derived cells (293)
stably expressing heparanase in response to insulin, and even more
so when insulin is combined with high glucose levels (Fig. 3).
Importantly, elevated levels of heparanase were also found in
the plasma of diabetes patients (Fig. 1C, D), ultimately leading to
systemic spread of heparanase, possibly affecting distant organs,
tissues and cells. In diabetic patients, vascular endothelial cells are
under continuous exposure to high glucose and insulin levels. In
previous studies, glucose (25 mM) was found to stimulate secretion
of heparanase by coronary artery endothelial cells, resulting in
decreased intracellular content of heparanase [36]. Furthermore,
high levels of glucose stimulated redistribution of heparanase-
positive lysosomal vesicles in endothelial cells [36], resembling the
effect of insulin on kidney 293 cells (Fig. 4). Interestingly, exposing
endothelial cells to high glucose was accompanied by a rapid
increase in extracellular ATP [36] which apparently mediates the
enhanced secretion of heparanase by glucose [36]. This result is in
perfect agreement with previous reports implicating adenosine,
ATP, and the P2Y receptors in heparanase secretion by tumor-
derived and kidney 293 cells [24]. Thus, elevated levels of
heparanase found in the plasma of diabetic patients may originate
from enhanced secretion of heparanase by kidney and endothelial
cells. The latter may account for the relatively high levels of
heparanase determined in the plasma of patients following kidney
Figure 2. Association between blood glucose and heparanase levels. A, B. Urine and plasma heparanase levels presented according to
gender. Shown are average (6SE) values of heparanase levels in urine (A) and plasma (B) quantified by ELISA in males (M) and females (F) of healthy
volunteers (control), T2DM patients and T2DM patients who underwent kidney transplantation. C, D. Association between urine and plasma
heparanase and blood glucose levels. Heparanase levels in plasma and urine were correlated with blood glucose levels using the non-parametric
Spearman’s rank test. Heparanase levels in the urine were found to correlate with blood glucose (C; r=0.52, p=0.0001); blood glucose was also
associated with plasma heparanase (D; r=0.38, p=0.003).
doi:10.1371/journal.pone.0017312.g002
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at high amounts and likely affects the vascular endothelium while
kidney function is relatively normal. Continuous exposure of the
vascular endothelium to heparanase may have severe outcome. It
has been shown, for example, that heparanase over-expression
leads to arterial thickening and reduced mechanical integrity [37].
Moreover, heparanase over-expression enhances neointimal
thickening due to increased proliferation and recruitment of
macrophages following stent implementation [37] whereas
neutralizing anti-heparanase antibodies reduced neointima for-
mation in a rat carotid balloon injury model [38]. Diabetes is also
associated with development of prothrombotic conditions [39].
Accumulating evidence suggest that heparanase functions as a pro-
coagulation mediator, enhancing expression of tissue factor and
generation of factor Xa, two critical components in blood
coagulation [40–42] thus providing another mode by which
heparanase affects the vasculature. Collectively, these results imply
that continuous exposure to high levels of heparanase in the
circulation may contribute to the development of diabetic-
associated vasculopathies.
While glucose has been shown to be engaged in heparanase
regulation [36,43], the ability of insulin to stimulate heparanase
Figure 3. Insulin cooperates with glucose to stimulate secretion of enzymatically active heparanase. A. Immunoblotting. Heparanase-
transfected 293 cells were cultured under normal (0.45%) or high (3%) glucose conditions in serum free medium for 20 h. Cells were left untreated (0)
or incubated with the indicated concentration of insulin for 2 h. Cell conditioned medium (1 ml) was then collected, and TCA-precipitates were
subjected to immunoblotting applying anti-heparanase (upper panel) and anti-cathepsin D (second panel) antibodies. Densitometry analysis of the
active 50 kDa heparanase is shown in the lower panel. B. Heparanase enzymatic activity. Corresponding medium samples of untreated cells (control;
¤) or cells treated with insulin (50 pM) under low (&) or high (m) glucose were applied onto 35 mm dishes coated with
35S-labeled ECM for 20 h. The
medium was then collected and sulfate labeled HS degradation fragments were analyzed by gel filtration, as described under "Materials and
Methods". C. Kinetics. Heparanase transfected 293 cells were grown under serum-free conditions and left untreated (Con) or stimulated with insulin
under low (0.45%; Ins) or high (3%; Ins+glu) glucose levels. At the time indicated, conditioned medium was collected and subjected to
immunoblotting applying anti-heparanase antibody.
doi:10.1371/journal.pone.0017312.g003
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growth factor are key regulators of energy metabolism and growth.
In addition, considerable evidence indicates that these hormones
and the signal transduction networks they regulate have important
roles in neoplasia [44]. Hence, increased insulin levels seen in
association with type 2 diabetes might lead to aggressive tumor
behavior [44]. Given the well documented role of heparanase in
tumor metastasis and angiogenesis [2,4,45], it is plausible that
insulin, with or without glucose, stimulates secretion of active
heparanase by tumor cells, thus accelerating tumor progression.
Studies examining this possibility are currently underway.
Taken together, the results of this study support and further
extend the causal involvement of heparanase in diabetes and the
associated complications, and provide for the first time clinical
association between blood glucose and heparanase secretion.
Decreased albumin excretion following administration of low
molecular weight heparin and related compounds, including oral
sulodexide [46–48] is attributed, in part, to the potent heparanase-
inhibiting capacity of heparin mimicking compounds [4,30,49,50].
These and related compounds are thus hoped to develop into new
treatment option for patients with diabetic nephropathy, diabetes-
related vascular and neurological pathologies, and cancer.
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